Archive · 17 Jan 2026
JB Pharma Reports 22% Net Profit Growth
JB Pharma, a company that makes medicines, just announced that it made a lot more money in the last three months.
Their profit went up by 22% compared to the same time last year.
This is because they sold more medicines both in India and in other countries.
They also made more money from helping other companies make medicines.
The boss of the company said they are doing a good job keeping costs low and are planning to keep growing by focusing on important medicines and making their business stronger.
JB Pharma's net profit rose by 22.2% year-on-year to ₹198 crore in Q3 FY26.
Revenue increased by 10.6% year-on-year to ₹1065 crore.
EBITDA grew by 13% year-on-year to ₹305 crore.
Domestic formulations revenue grew by 10% year-on-year to ₹620 crore.
International formulations revenue rose by 12% year-on-year to ₹445 crore.
- Who
- JB Chemicals & Pharmaceuticals Ltd (JB Pharma)
- What
- Reported a 22.2% year-on-year increase in net profit for Q3 FY26
- When
- Third quarter of the financial year 2025-26
- Where
- Domestic and international markets
- Why
- Driven by strong performance in domestic and international formulations, and CDMO segment growth
- Net Profit
- ₹198 crore
- Revenue Growth
- 10.6% YoY
- EBITDA Growth
- 13% YoY
- Domestic Formulations Revenue
- ₹620 crore
- International Formulations Revenue
- ₹445 crore
- 9M FY26 Revenue
- ₹3244 crore
- CEO
- Nikhil Chopra
- Fiscal Year
- 2025-26